SHERIDAN, WYOMING – May 8, 2025 – Fresenius Medical Care has kicked off fiscal year 2025 with robust financial performance, driven by strong organic revenue growth and significant operational efficiencies. The world’s leading provider of dialysis products and services posted a 5% increase in organic revenue, highlighting continued operational improvements in both its Care Enablement and Care Delivery segments.

SHERIDAN, WYOMING – May 8, 2025 – Fresenius Medical Care (FME) celebrates a major milestone as its dialysis center in Sokolov, Czech Republic, marks its 40th anniversary. With a commitment to providing high-quality care, NephroCare, under the FME brand, continues to serve around 100 dialysis patients, offering specialized nephrological services and cutting-edge dialysis treatments.

SHERIDAN, WYOMING – May 8, 2025 – Royal Philips (NYSE: PHG, AEX: PHIA) today confirmed that all proposals presented at its Annual General Meeting of Shareholders (AGM) 2025 have been approved, strengthening the company’s governance structure and positioning its leadership team to execute on long-term strategic objectives in the health technology sector.

SHERIDAN, WYOMING – May 8, 2025 – B. Braun Group has demonstrated resilience and strategic growth amidst challenging global conditions, reporting a 4.4% increase in sales for the 2024 fiscal year. The company’s focus on innovation, operational efficiency, and modern technology investments has contributed to a solid financial performance, reaffirming its commitment to advancing healthcare solutions worldwide.

SHERIDAN, WYOMING – May 8, 2025 – Alcon Inc. (SIX/NYSE: ALC), the global leader in eye care, today revealed the successful outcome of all proposed resolutions at its 2025 Annual General Meeting (AGM). Among the significant decisions, shareholders approved key appointments to the Board, including the election of Deborah Di Sanzo, and granted approval for the 2024 Compensation Report and the Report on Non-Financial Matters.

SHERIDAN, WYOMING – May 8, 2025 – Alcon, the global leader in eye care, has announced its continued partnership with the Association for Research in Vision and Ophthalmology (ARVO) for the Eye Pitch live event, set to take place at the ARVO 2025 annual meeting in Salt Lake City, Utah, on May 3, 2025. This event will serve as a platform for entrepreneurs and researchers within the ophthalmic community to present groundbreaking ideas aimed at transforming eye care.

SHERIDAN, WYOMING – May 8, 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today introduced the Elecsys® PRO-C3 test, a groundbreaking diagnostic solution designed to assess liver fibrosis severity in patients with metabolic dysfunction–associated steatotic liver disease (MASLD). This innovative test, developed in partnership with Nordic Bioscience, provides healthcare providers with a fast and efficient way to evaluate liver fibrosis, a disease that contributes to one in every 25 deaths globally.

SHERIDAN, WYOMING – May 8, 2025 – Roche has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending an update to the European Union (EU) label for Phesgo®, a subcutaneous (SC) fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab), used for treating HER2-positive breast cancer. The label update will allow for Phesgo to be administered outside of clinical settings, such as at patients’ homes, under the supervision of a healthcare professional.

SHERIDAN, WYOMING – May 8, 2025 – Roche has achieved a significant milestone in oncology diagnostics with the U.S. Food and Drug Administration (FDA) granting Breakthrough Device Designation for its VENTANA® TROP2 (EPR20043) RxDx Device. This marks the first FDA recognition for a computational pathology companion diagnostic (CDx) device using artificial intelligence, highlighting Roche's continued leadership in cancer diagnostics and precision medicine.